Immuneering (IMRX) Q2 2026 earnings summary

Executive summary

• Initiated global Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer, with first patient dosed in June 2026 and over 30 study locations.

• Reported positive interim Phase 2a data: 17.3 month median overall survival and 36% response rate for atebimetinib plus mGnP in 55 patients, compared to 8.5 months for standard of care.

• Published peer-reviewed and preclinical data showing atebimetinib's broad, durable activity and favorable tolerability in RAS- and RAF-mutant tumors.

• Appointed Andrew Gengos as Chief Financial Officer, effective July 2026, to oversee financial strategy and capital allocation.

Financial highlights

• Ended Q2 2026 with $182.7 million in cash, cash equivalents, and marketable securities, down from $217.0 million at year-end 2025.

• Net loss of $17.3 million ($0.27 per share) for Q2 2026, up 19.7% year-over-year; net loss of $30.7 million for the first half of 2026.

• Research and development expenses rose 33.9% year-over-year to $14.0 million for Q2 2026, mainly due to MAPKeeper 301 trial initiation.

• General and administrative expenses increased 16.3% year-over-year to $5.0 million for Q2 2026, primarily due to higher employee and software costs.

• Interest income increased by $0.8 million in Q2 2026 due to higher cash balances from 2025 financings.

Outlook and guidance

• Cash, cash equivalents, and marketable securities expected to fund operations into 2029 based on current operating plans.

• Anticipated milestones: first patient dosing in atebimetinib + Libtayo/anti-PD-1 trial (2H 2026), additional preclinical data (Q4 2026), IND-enabling studies for next DCI candidate (mid-2027), and MAPKeeper 301 topline data (mid-2028).